What is the management and treatment of diabetes insipidus?

Management and Treatment of Diabetes Insipidus

Diagnostic Confirmation

The diagnosis of diabetes insipidus requires the simultaneous presence of three findings: polyuria (>3 L/24h in adults), inappropriately dilute urine (osmolality <200 mOsm/kg), and high-normal or elevated serum sodium—this triad is pathognomonic for the condition. 1, 2

Initial Diagnostic Workup

• Measure serum sodium, serum osmolality, and urine osmolality simultaneously as first-line tests 2
• Obtain 24-hour urine volume to quantify polyuria 2
• Check serum creatinine and electrolytes (potassium, chloride, bicarbonate) 2
• Rule out diabetes mellitus first by checking blood glucose, as diabetes mellitus causes polyuria through osmotic diuresis from glucosuria, not ADH deficiency 1

Distinguishing Central from Nephrogenic DI

Plasma copeptin measurement is the primary differentiating test and should be obtained before proceeding to water deprivation testing. 2, 3

• Copeptin >21.4 pmol/L is diagnostic for nephrogenic diabetes insipidus 2, 3
• Copeptin <21.4 pmol/L indicates either central diabetes insipidus or primary polydipsia and requires additional testing with hypertonic saline or arginine stimulation 2
• Alternatively, a desmopressin trial can differentiate: response indicates central DI, no response indicates nephrogenic DI 1

Imaging for Central DI

• All patients with suspected central DI should undergo MRI of the sella with dedicated pituitary sequences, as approximately 50% have identifiable structural causes including tumors, infiltrative diseases, or inflammatory processes 1
• This is particularly critical in patients with newly developed hormonal deficiencies, as central DI is most commonly caused by metastatic diseases 1

---

Treatment of Central Diabetes Insipidus

Desmopressin is the treatment of choice for central diabetes insipidus and can be administered via multiple routes (intranasal, oral, subcutaneous, or intravenous). 2, 3, 4

Dosing Regimen

• Treatment-naïve patients: Start with 2-4 mcg daily administered as one or two divided doses by subcutaneous or intravenous injection 4
• Patients switching from intranasal desmopressin: Start with 1/10th the daily maintenance intranasal dose administered subcutaneously or intravenously as one or two divided doses 4
• Adjust morning and evening doses separately for adequate diurnal rhythm of water turnover 4
• Titrate based on adequate duration of sleep and adequate (not excessive) water turnover 4

Critical Monitoring Requirements

The FDA mandates that serum sodium must be checked within 7 days and at 1 month after starting desmopressin, then periodically during treatment, as hyponatremia is the main complication and can be life-threatening. 4

• Ensure serum sodium is normal before starting or resuming desmopressin 4
• Monitor more frequently in patients ≥65 years and those at increased risk of hyponatremia 4
• If hyponatremia occurs, desmopressin may need temporary or permanent discontinuation 4

Critical Contraindications

• Desmopressin is contraindicated in patients with excessive fluid intake, illnesses causing fluid/electrolyte imbalances, and those using loop diuretics or systemic/inhaled glucocorticoids 4
• Desmopressin is ineffective and not indicated for nephrogenic diabetes insipidus 4

---

Treatment of Nephrogenic Diabetes Insipidus

For nephrogenic DI, combination therapy with thiazide diuretics plus NSAIDs, along with dietary modifications (low-salt diet ≤6 g/day and protein restriction <1 g/kg/day), is the recommended approach and can reduce urine output by up to 50%. 1, 2, 3

Pharmacologic Management

• Start combination therapy with thiazide diuretics and prostaglandin synthesis inhibitors (NSAIDs) for symptomatic infants and children 1, 2, 3
• Thiazides work through mild volume depletion and increased proximal sodium/water reabsorption 3, 5
• NSAIDs enhance collecting duct water permeability and should be added to the regimen 3

Dietary Modifications

• Implement low-salt diet (≤6 g/day) with dietetic counseling 1, 2
• Restrict protein intake to <1 g/kg/day 1, 2
• These modifications reduce renal osmotic load and minimize urine volume 1

Genetic Testing

• Obtain genetic testing with a multigene panel including AVPR2, AQP2, and AVP genes if nephrogenic DI is confirmed, even in adults 1
• Test early in suspected cases, particularly in symptomatic females and male offspring of known carriers 3

---

Universal Management Principles for All DI Types

Fluid Management: The Most Critical Intervention

Patients with diabetes insipidus must have free access to plain water or hypotonic fluids 24/7—this is non-negotiable and failure to provide this is a life-threatening error that leads to severe hypernatremic dehydration. 1, 2, 3

• For patients capable of self-regulation: Fluid intake should be determined by their own thirst sensation rather than prescribed amounts, as their osmosensors are typically more sensitive and accurate than any medical calculation 1, 3
• Patients with DI commonly exhibit normal serum sodium at steady state when they have free access to water because their intact thirst mechanism drives adequate fluid replacement 1

Special Population Considerations

• Infants and toddlers: Cannot clearly express thirst, requiring caregivers to offer water frequently on top of regular fluid intake 1
• Infants with nephrogenic DI should receive normal-for-age milk intake to guarantee adequate caloric intake, but not electrolyte solutions 1
• Patients with cognitive impairment: Cannot self-regulate and require close monitoring of weight, fluid balance, and biochemistry with proactive and frequent offering of water 1

Intravenous Rehydration

• For IV rehydration in DI, use 5% dextrose in water (hypotonic fluid) at usual maintenance rates—NOT normal saline or electrolyte solutions 1
• This is critical because DI patients are losing free water, not electrolytes 1

Nutritional Support

• Support from an experienced dietitian is essential to ensure nutritional adequacy and provide practical advice on energy supplementation for infants and young children 3
• Consider tube feeding (nasogastric or gastrostomy) case-by-case for repeated vomiting/dehydration episodes or growth failure 3

---

Routine Follow-Up and Monitoring

Clinical Follow-Up Schedule

• Infants (0-12 months): Clinical follow-up including weight and height measurements every 2-3 months 1
• Adults: Annual clinical follow-up including weight measurements 1, 2

Laboratory Monitoring

• Infants (0-12 months): Blood tests (sodium, potassium, chloride, bicarbonate, creatinine, uric acid) every 2-3 months 1
• Adults: Annual blood tests (sodium, potassium, chloride, bicarbonate, creatinine, uric acid) 1, 2
• All patients: Annual urinalysis including osmolality, protein-creatinine or albumin-creatinine ratio, and 24-hour urine volume 1

Imaging Surveillance

• Renal ultrasound should be performed at least every 2 years to monitor for urinary tract dilatation and/or bladder dysfunction from polyuria 1, 2
• The interval can be extended to 5 years for stable patients 1
• Ultrasound should be performed before and after bladder emptying, as dilation improves with double voiding in about one-third of patients 1
• Approximately 46% of patients develop urological complications from chronic polyuria, including nocturnal enuresis and incomplete bladder voiding 1

Chronic Kidney Disease Risk

• Patients with DI have an increased risk of chronic kidney disease, with approximately 50% of adult patients having CKD stage ≥2 1, 2
• These patients require more frequent follow-up according to KDIGO guidelines 1, 2

---

Multidisciplinary Care Team

• Patients should be managed by a multidisciplinary team including a (pediatric) nephrologist, dietitian, psychologist, social worker, and urologist 1

---

Common Pitfalls to Avoid

• Never restrict water access in DI patients—this is the most dangerous error and leads to life-threatening hypernatremic dehydration 1
• Do not confuse DI with SIADH, which presents with hyponatremia, low serum osmolality, and inappropriately high urine osmolality 1
• Do not use electrolyte-containing solutions like Pedialyte for routine hydration in DI patients, as they contain substantial sodium loads (approximately 1,035 mg/L) that exceed typical needs 1
• Do not prescribe fixed fluid amounts—let patients drink to thirst unless they cannot self-regulate 1, 3
• Remember that desmopressin is completely ineffective for nephrogenic DI and should never be used 4